DK1421074T3 - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
DK1421074T3
DK1421074T3 DK02751935.4T DK02751935T DK1421074T3 DK 1421074 T3 DK1421074 T3 DK 1421074T3 DK 02751935 T DK02751935 T DK 02751935T DK 1421074 T3 DK1421074 T3 DK 1421074T3
Authority
DK
Denmark
Prior art keywords
new connections
therapy
processes
formula
preparation
Prior art date
Application number
DK02751935.4T
Other languages
Danish (da)
English (en)
Inventor
Alan Faull
Craig Johnstone
Andrew Morley
Jeffrey Philip Poyser
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1421074T3 publication Critical patent/DK1421074T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02751935.4T 2001-07-25 2002-07-19 Nye forbindelser DK1421074T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102616A SE0102616D0 (sv) 2001-07-25 2001-07-25 Novel compounds
PCT/SE2002/001403 WO2003010158A1 (en) 2001-07-25 2002-07-19 Novel compounds

Publications (1)

Publication Number Publication Date
DK1421074T3 true DK1421074T3 (da) 2010-12-13

Family

ID=20284944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02751935.4T DK1421074T3 (da) 2001-07-25 2002-07-19 Nye forbindelser

Country Status (21)

Country Link
US (3) US7125896B2 (enExample)
EP (1) EP1421074B1 (enExample)
JP (1) JP4571800B2 (enExample)
KR (1) KR100931172B1 (enExample)
CN (1) CN1263751C (enExample)
AT (1) ATE482944T1 (enExample)
AU (1) AU2002355245B2 (enExample)
BR (1) BR0211473A (enExample)
CA (1) CA2454703C (enExample)
CY (1) CY1111543T1 (enExample)
DE (1) DE60237828D1 (enExample)
DK (1) DK1421074T3 (enExample)
ES (1) ES2351436T3 (enExample)
IL (2) IL160028A0 (enExample)
MX (1) MXPA04000756A (enExample)
NO (1) NO326684B1 (enExample)
NZ (1) NZ530750A (enExample)
PT (1) PT1421074E (enExample)
SE (1) SE0102616D0 (enExample)
WO (1) WO2003010158A1 (enExample)
ZA (1) ZA200400492B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
MXPA04004064A (es) * 2001-10-30 2004-09-06 Pharmacia Corp Derivados heteroaromaticos de carboxamida para el tratramiento de la inflamacion.
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
EP1569924A4 (en) * 2002-12-06 2007-02-21 Smithkline Beecham Corp NF-KB FACTOR INHIBITORS
CN100413861C (zh) 2002-12-10 2008-08-27 维勒凯姆制药股份有限公司 用于治疗或预防黄病毒感染的化合物
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
WO2005007644A1 (ja) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd ヘテロアリールオキシ含窒素飽和へテロ環誘導体
AU2004265140A1 (en) * 2003-08-15 2005-02-24 Astrazeneca Ab Substituted thiophenes and uses thereof
CA2550839A1 (en) * 2003-12-23 2005-07-07 Somanta Limited Antharquinone compounds as anti cancer compounds
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2005105777A1 (en) * 2004-05-05 2005-11-10 Pharmacia & Upjohn Company Llc Substituted thiophene amide compounds for the treatment of inflammation
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
DE102005029382B3 (de) * 2005-06-24 2006-12-21 Sanofi-Aventis Deutschland Gmbh Alkoxymethylyl-substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
MX2007016541A (es) 2005-06-30 2008-03-07 Smithkline Beecham Corp Compuestos quimicos.
CA2621057A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Ikk inhibitors for the treatment of endometriosis
TW200730474A (en) * 2005-12-29 2007-08-16 Schering Ag Diamine derivatives as inhibitors of leukotriene A4 hydrolease
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US8106091B2 (en) 2006-11-01 2012-01-31 Chroma Therapeutics Ltd. Inhibitors of IKK-beta serine-threonine protein kinase
CA2668338A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. Ikk-.beta. serine-threonine protein kinase inhibitors
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
KR20090109551A (ko) * 2007-01-15 2009-10-20 산텐 세이야꾸 가부시키가이샤 IκB 키나아제 β 저해 활성을 갖는 신규 인돌 유도체
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
EA201001708A1 (ru) * 2008-04-26 2011-06-30 Хрома Терапьютикс Лтд. Замещённые тиофенкарбоксамиды их применение в качестве ингибиторов ikk-бета серин-треонин протеинкиназ
US8344144B2 (en) * 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
CN102089281A (zh) * 2008-07-14 2011-06-08 参天制药株式会社 具有氨基甲酰基、脲基及取代氧基的新型吲哚衍生物
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
BRPI1013328A2 (pt) * 2009-04-16 2016-03-29 Telik Inc 4-amino-benzoil-2-(fenilamino) tiofeno-3-carbonitrilas substituídas e 4-a-mino-5benzoil-2-(fenilamino) tiofeno-3-carboxamidas substituídas como inibidores da polimerização de tubulina
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
CN101812007B (zh) * 2010-04-27 2011-11-23 浙江大学 氨基吡咯类化合物及其制备方法
WO2012046793A1 (ja) * 2010-10-07 2012-04-12 参天製薬株式会社 ウレイド基とアミノカルボニル基を置換基として有するチオフェン誘導体を有効成分として含有する新規jak3阻害剤
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
KR20250028525A (ko) * 2012-03-14 2025-02-28 머크 샤프 앤드 돔 엘엘씨 Cgrp 수용체 길항제의 제조 방법
US9487523B2 (en) 2012-03-14 2016-11-08 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
EP2970309A4 (en) 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
JP6562898B2 (ja) 2013-03-14 2019-08-21 セルタクシス,インコーポレイテッド ロイコトリエンa4加水分解酵素の阻害剤
EP2821791A1 (en) * 2013-07-04 2015-01-07 Université de Strasbourg 3-aryl propiolonitrile compounds for thiol labeling
RS57542B1 (sr) 2013-10-17 2018-10-31 Blueprint Medicines Corp Kompozicije korisne za lečenje poremećaja povezanih sa kit-om
JP6344923B2 (ja) * 2014-01-29 2018-06-20 株式会社Uacj 高強度アルミニウム合金及びその製造方法
US9926286B2 (en) * 2014-05-09 2018-03-27 Shanghai Syncores Technologies Inc. Ltd. Vortioxetine intermediate and synthesis process thereof
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
EP3801559B1 (en) 2018-05-31 2025-01-01 Celltaxis, LLC Method of reducing pulmonary exacerbations in respiratory disease patients
MA55604B1 (fr) 2019-04-12 2024-08-30 Blueprint Medicines Corporation Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra
CN113966334B (zh) 2019-04-12 2025-01-21 缆图药品公司 化合物(i)的晶体形式

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
GB2195634B (en) * 1986-10-01 1990-08-15 Roussel Lab Ltd Thiophene derivatives
JPH02193990A (ja) * 1989-01-20 1990-07-31 Taisho Pharmaceut Co Ltd チオフェンカルボン酸誘導体
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5571810A (en) 1990-06-11 1996-11-05 Fujisawa Pharmaceutical Co., Ltd. Thiophene derivatives
US5514801A (en) 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
JPH09194476A (ja) * 1996-01-12 1997-07-29 Taisho Pharmaceut Co Ltd チオフェンアルカン酸誘導体
AU3044197A (en) 1996-07-11 1998-02-09 Pfizer Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6809088B2 (en) 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU2713799A (en) 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
JP3786579B2 (ja) 1998-07-08 2006-06-14 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 硫黄置換スルホニルアミノカルボン酸n−アリールアミド、それらの製造、それらの使用、及びそれらを含む医薬製剤
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP2004523476A (ja) 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション NF−κB阻害剤
US20040024047A1 (en) * 2001-10-12 2004-02-05 Callahan James F. Nf-kb inhibitors
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US6713638B2 (en) 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
ES2315430T3 (es) 2001-10-04 2009-04-01 Smithkline Beecham Corporation Inhibidores de nf-kb.
WO2003028731A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ATE482944T1 (de) 2010-10-15
US20070015819A1 (en) 2007-01-18
KR100931172B1 (ko) 2009-12-11
MXPA04000756A (es) 2004-04-20
CA2454703A1 (en) 2003-02-06
ZA200400492B (en) 2005-04-22
US7956084B2 (en) 2011-06-07
HK1071129A1 (en) 2005-07-08
US7125896B2 (en) 2006-10-24
DE60237828D1 (de) 2010-11-11
ES2351436T3 (es) 2011-02-04
IL160028A0 (en) 2004-06-20
EP1421074B1 (en) 2010-09-29
US20110152234A1 (en) 2011-06-23
JP4571800B2 (ja) 2010-10-27
WO2003010158A1 (en) 2003-02-06
PT1421074E (pt) 2010-11-29
US20040242573A1 (en) 2004-12-02
JP2005503372A (ja) 2005-02-03
AU2002355245B2 (en) 2008-05-15
CY1111543T1 (el) 2015-08-05
CN1263751C (zh) 2006-07-12
SE0102616D0 (sv) 2001-07-25
IL160028A (en) 2012-01-31
NO326684B1 (no) 2009-01-26
EP1421074A1 (en) 2004-05-26
KR20040018520A (ko) 2004-03-03
NO20040313L (no) 2004-03-25
CN1541214A (zh) 2004-10-27
CA2454703C (en) 2011-01-04
BR0211473A (pt) 2004-10-26
NZ530750A (en) 2005-08-26

Similar Documents

Publication Publication Date Title
DK1421074T3 (da) Nye forbindelser
NO20040314L (no) Nye forbindelser
TR200401962T4 (tr) Heteroaromatik karboksamid türevleri ve bunların IKK-2 enziminin inhibitörleri olarak kullanımı
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
SE0102439D0 (sv) New compounds
SE0302116D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
NO20026064D0 (no) Nye forbindelser
SE0202133D0 (sv) Novel compounds
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
NO20023932D0 (no) Nye forbindelser
SE0300092D0 (sv) Novel compounds
SE0101038D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel